Abciximab (previously known as c7E3 Fab), manufactured by Centocor and distributed by Eli Lilly under the trade name ReoPro^®, is a platelet aggregation inhibitor mainly used during and after coronary artery procedures like angioplasty to prevent platelets from sticking together and causing thrombus (blood clot) formation within the coronary artery. Its mechanism of action is inhibition of glycoprotein IIb/IIIa.

While Abciximab has a short plasma half life, due to its strong affinity for its receptor on the platelets, it may occupy some receptors for weeks. In practice, platelet aggregation gradually returns to normal about 24 to 48 hours after discontinuation of the drug.

Abciximab is made from the Fab fragments of an immunoglobulin that targets the glycoprotein IIb/IIIa receptor on the platelet membrane.

More on [ Abciximab ]

Abciximab - Twitter Search

Early abciximab has benefits in high-risk STEMI patients: study ... http://bit.ly/1fMJrV
Resultsfitness (Tammi Jacobs) Sat, 07 Nov 2009 21:29:46 -0000
Early abciximab has benefits in high-risk STEMI patients: study ... http://bit.ly/1fMJrV
algumas drogas parecem ter sido batizadas por george lucas: anakinra, abatacept, rituximab, etanercept, infliximab, adalimumab, abciximab...
tat_can (tatiane cantarelli) Wed, 04 Nov 2009 00:48:34 -0000
algumas drogas parecem ter sido batizadas por george lucas: anakinra, abatacept, rituximab, etanercept, infliximab, adalimumab, abciximab...

Subscribe to Abciximab RSS feed